We are 3-Methylbenzoic acid CAS:99-04-7 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
CAS No: 99-04-7
Product Name: 3-Methylbenzoic acid
Density: 1.2±0.1 g/cm3
Boiling Point: 263.8±9.0 °C at 760 mmHg
Melting Point: 108 °C
Molecular Formula: C8H8O2
Molecular Weight: 136.148
Flash Point: 120.0±13.4 °C
Exact Mass: 136.052429
Vapour Pressure: 0.0±0.6 mmHg at 25°C
Index of Refraction: 1.556
Stability: Stable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility: <0.1 g/100 mL at 19 ºC
Appearance: White crystalline solid
Mainly used in the production of high efficiency mosquito repellent, N, N-diethyl m-toluamide, m-toluoyl chloride, m-toluonitrile and so on.
It can be used as an intermediate of the drug toluene diethylamine. Also used in the production of pesticides and other chemical products.
Applicationd in organic synthesis intermediates, pesticide industry to prepare fungicide phosphoramide, can also be used in perfumery and film.
Organic synthesis intermediates, mainly used in the production of highly effective mosquito repellents, N, N-diethyl m-toluamide, m-toluoyl chloride, m-toluonitrile, toluene diethylamine, fungicides, insecticides, PVC stabilizers Basic raw materials for pharmaceuticals, pesticides and other chemical products.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform.3-cloro-1-propanol CAS:627-30-5 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.2-methoxy-3-propan-2-ylpyrazine At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up.4044-58-0 At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up.When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant.